From: Psoriasis-associated vascular disease: the role of HDL
Ref: number of subjects | HDL alterations |
Mehta (42): 112 patients | Reduced cholesterol efflux capacity |
Holzer (35): 15 patients | Reduced cholesterol efflux capacity Reduced apoA-I, apoA-II, apoM Reduced phospholipid (phosphatidylcholine and sphingomyeline) and cholesterol content Increased SAA, prothrombin, α-1-anti-trypsine, α-1-acid-glycoprotein 1 Not altered PON-1 activity |
Holzer (51): 15 patients | Reduced cholesterol efflux capacity Reduced apoA-I and apoM Reduced phospholipid (phosphatidylcholine and sphingomyeline) and cholesterol content Increased SAA, prothrombin, α-1anti-trypsine, α-1-acid glycoprotein 1 Reduced PON-1 activity |
He (44): 25 patients | Reduced PON-1 activity Reduced anti-inflammatory activity |
Usta (45): 25 patients | Reduced PON-1 activity |
Ferretti (46): 23 patients | Reduced PON-1 activity Increased lipid peroxidation |
Toker (20): 30 patients | Increased PON-1 activity |
Tom (43): 44 paediatric patients | Reduced cholesterol efflux capacity |